[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cardiff Oncology Inc (CRDF)

Cardiff Oncology Inc (CRDF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 68,467
  • Shares Outstanding, K 77,795
  • Annual Sales, $ 590 K
  • Annual Income, $ -45,850 K
  • EBIT $ -42 M
  • EBITDA $ -43 M
  • 60-Month Beta 1.49
  • Price/Sales 119.21
  • Price/Cash Flow N/A
  • Price/Book 2.35
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.60
  • Most Recent Earnings $-0.14 on 08/11/26
  • Next Earnings Date 11/05/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 106.68% (-53.06%)
  • Historical Volatility 120.65%
  • IV Percentile 5%
  • IV Rank 9.01%
  • IV High 483.26% on 02/09/26
  • IV Low 69.37% on 12/08/25
  • Expected Move (DTE 26) 0.0850 (9.66%)
  • Put/Call Vol Ratio 0.05
  • Today's Volume 195
  • Volume Avg (30-Day) 611
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 39,634
  • Open Int (30-Day) 35,719
  • Expected Range 0.7951 to 0.9651

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.15
  • Number of Estimates 5
  • High Estimate $-0.13
  • Low Estimate $-0.20
  • Prior Year $-0.17
  • Growth Rate Est. (year over year) +11.76%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7566 +16.32%
on 07/29/26
1.1300 -22.12%
on 08/12/26
+0.0401 (+4.77%)
since 07/21/26
3-Month
0.7566 +16.32%
on 07/29/26
2.0000 -55.99%
on 05/26/26
-0.9099 (-50.83%)
since 05/21/26
52-Week
0.7566 +16.32%
on 07/29/26
3.3100 -73.41%
on 12/26/25
-1.3799 (-61.06%)
since 08/21/25

Most Recent Stories

More News
Cardiff Oncology: Q2 Earnings Snapshot

Cardiff Oncology: Q2 Earnings Snapshot

CRDF : 0.8801 (-3.15%)
Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update

Positive Phase 2 CRDF-004 data presented in an oral session at ASCO support advancement of 30 mg onvansertib plus FOLFIRI/bevacizumab into planned registrational program for first-line RAS-mutated mCRC...

CRDF : 0.8801 (-3.15%)
Cardiff Oncology Announces $10 Million Registered Direct Offering

SAN DIEGO, July 15, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF) (the “Company”), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies,...

CRDF : 0.8801 (-3.15%)
Cardiff Oncology Announces Presentation of Positive Results from its Randomized, Controlled Phase 2 Trial of Onvansertib in First-Line RAS-Mutated mCRC at the 2026 ASCO Annual Meeting

-​ The trial achieved its primary goal of selecting the efficacious and safe dose of onvansertib + standard-of-care (SoC) regimen for the registrational program -​ -​ 30 mg onvansertib + FOLFIRI/bevacizumab...

CRDF : 0.8801 (-3.15%)
Cardiff Oncology to Participate in the Jefferies Global Healthcare Conference

SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers,...

CRDF : 0.8801 (-3.15%)
Cardiff Oncology Announces Webcast to Discuss Updated Phase 2 CRDF-004 Data for Onvansertib in First-Line RAS-Mutated mCRC

SAN DIEGO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies, today announced...

CRDF : 0.8801 (-3.15%)
Cardiff Oncology: Q1 Earnings Snapshot

Cardiff Oncology: Q1 Earnings Snapshot

CRDF : 0.8801 (-3.15%)
Cardiff Oncology Reports First Quarter 2026 Results and Provides Business Update

Completed successful End-of-Phase 2 meeting with the FDA and selected onvansertib dose and chemotherapy regimen for planned Phase 3 trial  Company to provide detailed data update from Phase 2 CRDF-004...

CRDF : 0.8801 (-3.15%)
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range...

CRDF : 0.8801 (-3.15%)
Cardiff Oncology to Host Key Opinion Leader Discussion on Onvansertib’s Promising Single-Agent Activity

SAN DIEGO, April 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers,...

CRDF : 0.8801 (-3.15%)

Business Summary

Cardiff Oncology Inc. is a clinical-stage biotechnology company. It engages in developing treatment for cancer patients. The company's product pipeline consists of a Phase 1b/2 study of onvansertib in combination with FOLFIRI/Avastin(R) in KRAS-mutated metastatic colorectal cancer; a Phase 2 study of...

See More

Key Turning Points

3rd Resistance Point 0.9616
2nd Resistance Point 0.9452
1st Resistance Point 0.9127
Last Price 0.8801
1st Support Level 0.8638
2nd Support Level 0.8474
3rd Support Level 0.8149

See More

52-Week High 3.3100
Fibonacci 61.8% 2.3346
Fibonacci 50% 2.0333
Fibonacci 38.2% 1.7320
Last Price 0.8801
52-Week Low 0.7566

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.